Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: A North American perspective: Executive summary

David P. Faxon, John W. Eikelboom, Peter B. Berger, David R. Holmes, Deepak L. Bhatt, David J. Moliterno, Richard C. Becker, Dominick J. Angiolillo

Research output: Contribution to journalReview article

96 Scopus citations

Abstract

The optimal regimen of the anticoagulant and antiplatelet therapies in patients with atrial fibrillation who have had a coronary stent is unclear. It is well recognized that "triple therapy" with aspirin, clopidogrel, and warfarin is associated with an increased risk of bleeding. National guidelines have not made specific recommendations, given the lack of adequate data. In choosing the best antithrombotic options for a patient, consideration needs to be given to the risks of stroke, stent thrombosis, and major bleeding. This executive summary describes these risks, provides specific recommendations concerning vascular access, stent choice, concomitant use of proton pump inhibitors, and the use and duration of triple therapy after stent placement, based on the risk assessment.

Original languageEnglish (US)
Pages (from-to)522-534
Number of pages13
JournalCirculation: Cardiovascular Interventions
Volume4
Issue number5
DOIs
StatePublished - Oct 1 2011

Keywords

  • Antithrombotic therapy
  • Atrial fibrillation
  • Stent
  • Triple therapy
  • Warfarin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: A North American perspective: Executive summary'. Together they form a unique fingerprint.

  • Cite this